Back to Research Home
CICigna Corp
Health Care · Health Care Services · Large
$306.95−2.83%
As of 23 Oct 2026Mkt cap $74.7B
Stage 13
WATCH
Fundamentals
44.9/75
Technical
8.2/15
Independent
53.1/90
GCAE viewbusiness is credible but technical recovery is not yet actionable
Price
- 1M
- +15.6%
- 3M
- +5.5%
- 6M
- +11.4%
- 1Y
- −0.3%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 12.7xHist median 16.6x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 11.6%
- Operating margin
- 3.8%
- FCF margin
- —
- Current ratio
- 0.8x
Growth
- Revenue growth
- +11.2%Latest FY YoY
- Revenue CAGR
- +12.1%
- EPS CAGR
- +8.9%
- FCF CAGR
- —
Capital
- Share-count trend
- −4.9%3Y annualised
- Net debt
- $23.2B2.4x OCF
Annual trend
- CAGR 2021–2025
- +12.1%
- Latest · 2025
- $275B
- YoY
- +11.2%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
business is credible but technical recovery is not yet actionable
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-05
More details & evidence
Production decision
- Stage 13
- WATCH
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded